Stroke Risk Assessment

The incidence of atrial fibrillation in the aging population continues to increase in frequency and predisposes patients to an increased risk for stroke. Assessment of risk for stroke is a significant and independent risk factor for stroke.

Learn More

Bleed Risk

An important element weighing the risk of bleeding on anticoagulation is to assess it along with the risk of morbidity and mortality from stroke. The HASBLED Scale describes patient characteristics that affect bleeding risk.

Learn More

Medication Information

The selection of the appropriate medical therapy requires a sound knowledge about the characteristics of these medications which include warfarin and newer medications such as dabigatran etexilate, rivaroxaban, apixaban, and edoxaban.

Learn More

Patient Compliance

Consistency in medication compliance, diet, and activities are critical elements in a comprehensive care plan. An effective plan of care minimizes stroke risk while not creating a significant risk of bleeding.

Learn More

Patient Management for Medical Procedures

Appropriate adjustments to medical therapies, close monitoring of patient status (pre- and post-operatively) and a coordinated plan for comprehensive anticoagulation management are essential to optimum patient outcomes.

Learn More

TEAM-A is an innovative educational collaboration among ten organizations committed to improving patient outcomes through clinician education:

Logos American College of Cardiology Foundation American Heart Association/American Stroke Association University of Wisconsin, School of Medicine and Public Health, Office of Continuing Professional Development Healthcare Performance Consulting, Inc. University of Virginia School of Medicine—Office of Continuing Medical Education Interstate Postgraduate Medical Association Telligen Physicians Institute for Excellence in Medicine California Academy of Family Physicians (CAFP) CME Enterprise

The TEAM-A initiative is supported by an independent medical educational grant from the Bristol-Myers Squibb/Pfizer Pharmaceuticals Partnership.

Selected TEAM-A activities are supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.